Christopher Rex
Founder at Afraxis, Inc.
Profile
Christopher Rex is the founder of Afraxis, Inc. which was founded in 2010, where he holds the title of Chief Scientific Officer.
He was also a Program Director at T123 LLC from 2018 to 2021.
Dr. Rex received his doctorate from the University of California, Irvine in 2008 and his undergraduate degree from the University of California, Santa Barbara in 2002.
Christopher Rex active positions
Companies | Position | Start |
---|---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Founder | 01/01/2010 |
Former positions of Christopher Rex
Companies | Position | End |
---|---|---|
T123 LLC
T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Director/Board Member | 01/04/2021 |
Training of Christopher Rex
University of California, Irvine | Doctorate Degree |
University of California, Santa Barbara | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
T123 LLC
T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Finance |
- Stock Market
- Insiders
- Christopher Rex